News
Burning Rock Announces Resignation and Appointment of Directors
Burning Rock Biotech Limited (NASDAQ: BNR and LSE: BNR) announced the resignation of Dr. Shaokun (Shannon) Chuai as a director from the board of directors and as the Company’s Chief Scientific Officer, effective June 30, 2023.
Shineco Enters into Cooperation Agreement with Kangling Medical to Develop New Medical Products Company
Shineco, Inc. (NASDAQ: SISI), announced today that on June 15, 2023, its wholly owned subsidiary, Shineco Life Science Research Co., Ltd. signed a joint venture cooperation agreement with Yangzhou Kangling Medical Co., Ltd. to establish a joint venture company, Shangkang Life Science and Technology.
Sosei Heptares Provides Update on Lotiglipron Development
osei Group Corporation (“the Company”; TSE: 4565) notes the decision by its partner Pfizer to prioritize the development of clinical-stage GLP-1 receptor agonist candidate danuglipron for the treatment of diabetes and obesity and as a result has discontinued the development of lotiglipron.
Aurisco gets Auxiton® (Dydrogesterone) as first generic approval in China
Aurisco Pharmaceutical received its first Marketing Authorization Approval in China for AUXITON®, the oral finished dosage form of Dydrogesterone, from China's Health Authority, the NMPA.
Phase 3b Trial of Fezolinetant Shows Positive Topline Results for Treatment of VMS Due to Menopause
Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") today announced positive topline results from the Phase 3b DAYLIGHT clinical trial for fezolinetant, an investigational oral, nonhormonal compound being studied for the treatment of moderate to severe vasomotor symptoms (VMS) due to menopause.
Xuanzhu Biopharm, a subsidiary of Sihuan Pharmaceutical, Its Innovative Drug Anaprozole Sodium Enteric-coated Tablets Obtains Drug Registration Approval From NMPA
Sihuan Pharmaceutical Holdings Group Ltd together with its subsidiaries, announced that Xuanzhu Biopharmaceutical Co. received a drug registration approval from China's NMPA of Anaprozole Sodium Enteric-coated Tablet for the treatment of duodenal ulcer.
Foresee Pharmaceuticals Announces Completion of US$42.3 Million Financing
Foresee Pharmaceuticals (TPEx: 6576), ("Foresee") announces that it has successfully completed an underwritten public offering of 17,500,000 shares of its common stock to the public at a price of NT$75 per share. The aggregate gross proceeds to Foresee from the offering were NT$1,312.5 million (or US$42.3 million at FX=31).
SK bioscience and the Peter Doherty Institute for Infection and Immunity Join Forces Against Influenza
SK bioscience, a global innovative vaccine and biotech company committed to promoting human health from prevention to cure, announced that the company has signed a research collaboration agreement on influenza research with the Doherty Institute.
Pharmadule Morimatsu and WuXi Biologics Reached Global Strategic Partnership
Pharmadule Morimatsu and WuXi Biologics officially entered into a global strategic cooperation for the Singapore CRDMO Center project of WuXi Biologics.
Dyadic Announced an MoU with Bangladesh’s State-Owned Pharmaceutical Company to Facilitate Biopharmaceutical Research and Biomanufacturing Capacity
JUPITER, Fla. and DHAKA, Bangladesh, June 21, 2023 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial platforms to address the growing demand for global protein bioproduction and unmet clinical needs for effective, affordable and accessible biopharmaceutical products for human and animal health, today announced that it has entered into a Memorandum of Understanding (“MoU”) with Essential Drugs Company Limited (EDCL), the state owned pharmaceutical company under the Ministry of Health and Family Welfare of Bangladesh to facilitate biopharmaceutical research, pre-clinical development, cGMP production, clinical trials, regulatory and other relevant areas of interest in Bangladesh.
